Bausch + Lomb Corporation (BLCO)Healthcare | Medical Instruments & Supplies | Vaughan, Canada | NYSE
16.21 USD
-0.02
(-0.123%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:56 a.m. EDT
The investment case for Bausch + Lomb is currently broken by a perfect storm of operational failure and financial distress. The company has just halted a key glaucoma eye drop program after a trial failure, which likely triggered the recent stock decline and erodes confidence in its pipeline. Fundamentally, the business is deteriorating rapidly: profit margins are negative at -4.2%, return on equity is -3.3%, and the stock has suffered a 12.7% decline over the last three years, with two consecutive years of negative growth. The balance sheet is fragile, carrying nearly $5 billion in debt against only $268 million in cash, resulting in a dangerously high debt-to-equity ratio of 78.6%. While the forward P/E suggests analysts expect a turnaround, the current reality is a value trap with no earnings to support the valuation. Furthermore, the company has suspended all dividend payments, eliminating any income floor for investors. The options market confirms this pessimism, with traders buying protection at the money rather than betting on a rally. Until the debt load is reduced and a profitable product pipeline is restored, this security warrants avoidance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.051593 |
| AutoETS | 0.052424 |
| AutoARIMA | 0.052505 |
| MSTL | 0.061178 |
| MSTL_105 | 0.078926 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 2.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.532 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 78.58 |
| Revenue per Share | 14.695 |
| Market Cap | 5,779,453,952 |
| Forward P/E | 15.14 |
| Beta | 0.56 |
| Profit Margins | -4.21% |
| Website | https://www.bausch.com |
As of July 11, 2026, 6:56 a.m. EDT: Speculators are positioning defensively with heavy put volume at near-the-money strikes for the immediate expiration, while call activity remains sparse and concentrated further out. Implied volatility is significantly elevated for puts compared to calls, indicating a fear of downside continuation rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.18640351 |
| Address1 | 520 Applewood Crescent |
| All Time High | 21.95 |
| All Time Low | 10.45 |
| Ask | 18.97 |
| Ask Size | 400 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.5 - Buy |
| Average Daily Volume10 Day | 370,760 |
| Average Daily Volume3 Month | 447,600 |
| Average Volume | 447,600 |
| Average Volume10Days | 370,760 |
| Beta | 0.558 |
| Bid | 16.09 |
| Bid Size | 800 |
| Board Risk | 5 |
| Book Value | 17.899 |
| City | Vaughan |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.21 |
| Current Ratio | 1.525 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 16.48 |
| Day Low | 16.11 |
| Debt To Equity | 78.58 |
| Display Name | Bausch + Lomb |
| Earnings Call Timestamp End | 1,785,355,200 |
| Earnings Call Timestamp Start | 1,785,355,200 |
| Earnings Timestamp | 1,785,328,200 |
| Earnings Timestamp End | 1,785,328,200 |
| Earnings Timestamp Start | 1,785,328,200 |
| Ebitda | 724,000,000 |
| Ebitda Margins | 0.13902001 |
| Enterprise To Ebitda | 14.716 |
| Enterprise To Revenue | 2.046 |
| Enterprise Value | 10,654,454,784 |
| Eps Current Year | 0.80468 |
| Eps Forward | 1.07035 |
| Eps Trailing Twelve Months | -0.62 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.856 |
| Fifty Day Average Change | 0.35399914 |
| Fifty Day Average Change Percent | 0.022325879 |
| Fifty Two Week Change Percent | 18.64035 |
| Fifty Two Week High | 18.915 |
| Fifty Two Week High Change | -2.7050018 |
| Fifty Two Week High Change Percent | -0.14300829 |
| Fifty Two Week Low | 13.09 |
| Fifty Two Week Low Change | 3.119999 |
| Fifty Two Week Low Change Percent | 0.2383498 |
| Fifty Two Week Range | 13.09 - 18.915 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,651,843,800,000 |
| Float Shares | 44,916,450 |
| Forward Eps | 1.07035 |
| Forward P E | 15.144577 |
| Free Cashflow | 238,500,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 13,000 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.60618 |
| Gross Profits | 3,156,999,936 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.87244004 |
| Held Percent Institutions | 0.109960005 |
| Implied Shares Outstanding | 356,536,358 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. |
| Long Name | Bausch + Lomb Corporation |
| Market | us_market |
| Market Cap | 5,779,453,952 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1678122959 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -219,000,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,766,059,575 |
| Number Of Analyst Opinions | 12 |
| Open | 16.2 |
| Operating Cashflow | 340,000,000 |
| Operating Margins | 0.04743 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.89 |
| Phone | 905 695 7700 |
| Previous Close | 16.23 |
| Price Eps Current Year | 20.144653 |
| Price Hint | 2 |
| Price To Book | 0.90563715 |
| Price To Sales Trailing12 Months | 1.1097262 |
| Profit Margins | -0.04205 |
| Quick Ratio | 0.755 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.46154 |
| Region | US |
| Regular Market Change | -0.0200005 |
| Regular Market Change Percent | -0.123231 |
| Regular Market Day High | 16.48 |
| Regular Market Day Low | 16.11 |
| Regular Market Day Range | 16.11 - 16.48 |
| Regular Market Open | 16.2 |
| Regular Market Previous Close | 16.23 |
| Regular Market Price | 16.21 |
| Regular Market Time | 1,783,972,802 |
| Regular Market Volume | 271,847 |
| Return On Assets | 0.014149999 |
| Return On Equity | -0.03275 |
| Revenue Growth | 0.094 |
| Revenue Per Share | 14.695 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 356,536,358 |
| Shares Percent Shares Out | 0.0112 |
| Shares Short | 3,985,273 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,063,241 |
| Short Name | Bausch + Lomb Corporation |
| Short Percent Of Float | 0.088599995 |
| Short Ratio | 8.8 |
| Source Interval | 15 |
| State | ON |
| Symbol | BLCO |
| Target High Price | 21.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 18.125 |
| Target Median Price | 18.0 |
| Total Cash | 268,000,000 |
| Total Cash Per Share | 0.752 |
| Total Debt | 5,070,000,128 |
| Total Revenue | 5,208,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.2229 |
| Two Hundred Day Average Change | -0.012901306 |
| Two Hundred Day Average Change Percent | -0.00079525274 |
| Type Disp | Equity |
| Volume | 271,847 |
| Website | https://www.bausch.com |
| Zip | L4K 4B4 |